B4GalT1 – A Druggable Target for the Treatment of Glioblastoma

B4GalT1 A Target to Stop Glioblastoma
Multi-faceted Properties of B4GalT1 Beta-1,4-Galactosyltransferase 1 (B4GalT1) belongs to the galactosyltransferase (GalT) family of enzymes that transfer galactose from uridine-diphosphate-α-D-galactose (UDP-Gal) to an acceptor sugar molecule. B4GalT1 is a critical enzyme in galactose metabolism. One of the first GalT to be characterized biochemically, B4GalT1, was also involved in lactose production by interacting with α-lactalbumin during
Read more
No Comments

New Transcreener UDP2 Assay with a Fluorescence Intensity Readout

Transcreener Glycosyltransferase Assay Blog
BellBrook Labs scientists have developed a new universal UDP detection assay for the measurement of Glycosyltransferase activity.  The Transcreener UDP2 FI Assay extends the Transcreener platform for UDP detection by utilizing a simple fluorescence intensity (FI) output. It can be used on fluorescence readers typically found in academic and therapeutic research laboratories, as well as
Read more
No Comments

Using Glycogen Synthase Assays in the Quest for Type 2 Diabetes Therapies  

glycogen synthase diabetes
Although millions of Americans are living with diabetes thanks to medical intervention, it still ranks among the top ten causes of death; Type 2 being the most common.¹ Energy producing glucose is maintained so that we can withstand times of fasting as well as feasting. Think about the person that survives weeks in the wilderness
Read more
No Comments

Using a Glycosyltransferase Activity Assay to Study Glycosylation and the Function of GTs

Glycosyltransferase Activity Assay and Lysosomal Storage Disorders
Glycosyltransferase (GT) enzymes are incredibly diverse in their abilities to catalyze the transfer of sugar molecules to protein, carbohydrate, and lipid substrates. GTs have various metabolic and regulatory roles in biology. Glycosyltransferase targets provide different areas of therapeutic potential in a wide array of disease, including cancer, metabolic disorders, and infectious disease. A glycosyltransferase activity
Read more
No Comments

A Guide to Measuring Drug-Target Residence Times with Biochemical Assays

Residence Time Guide
Learn How to Determine Drug-Target Residence Times with Biochemical Assays in this Free Guide Drug-target residence time has become a critical component in the discovery of new therapeutics. BellBrook Labs has recently published a guide to help describe the use of a proven “jump-dilution” method along with BellBrook’s Transcreener Assay platform to help streamline efforts
Read more
No Comments

New Publication: HTS Method for Measuring Drug Residence Time

View our latest publication, “A High-Throughput Method for Measuring Drug Residence Time Using the Transcreener® ADP2 Assay” in SLAS Discovery. Inhibitor residence times are increasingly being used to prioritize molecules early in lead discovery programs. Current methods for determining residence time are low-throughput or require the synthesis of labeled ligands. Our goal was to create
Read more
No Comments

New Publication: TR-FRET Assay for UDP-Glycosyltransferases

See our latest publication, “Development and Validation of a Universal High-Throughput UDP-Glycosyltransferase Assay with a Time-Resolved FRET Signal” in ASSAY and Drug Development Technologies BellBrook Labs scientist Tom Zielinski collaborated with investigators in Mel Reichman and Preston Donover of the Lankenau Institute for Medical Research to develop a robust assay method for screening and profiling
Read more
No Comments

New Target for Heart Disease and Cancer: Glucosylceramide Synthase (GCS)

Two recent publications have indicated that an unassuming glycosphingolipid that has long been associated with rare metabolic disorders may contribute to heart disease and cancer, the two leading causes of death in the United States. Glycosphingolipids (GSLs) are complex membrane lipids that play diverse roles in cell communication, especially during development. Patients with Gaucher or
Read more
No Comments

Validation of a GEF Inhibitor in Murine Models of Major Osteolytic Diseases

Healthy bones are strong, but forming healthy bones requires a delicate balance between bone-building osteoblasts and bone-degrading osteoclasts. If the action of osteoclasts prevails and bone resorption exceeds bone deposition, bone-diminishing diseases such as osteoporosis occur. The answer seems simple: target osteoclasts as the enemy. But drugs currently available to rein in excessive osteoclast activity
Read more
No Comments

A Specific Inhibitor for a Promiscuous Glycosyltransferase

O-GlcNAc transferase (OGT) is a promiscuous covalent regulatory enzyme that affects diverse cellular processes by attaching O-linked N-acetylglucosamine (O-GlcNAc) residues to intracellular proteins including kinases, phosphatases, transcription factors, and histones. Though recent evidence suggests that OGT may be an anti-cancer target, developing a specific inhibitor that does not interfere with cell surface glycans is a
Read more
No Comments